AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing
Executive Summary
Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas
You may also be interested in...
Sounding The Alarm On The Future Of CNS Drug Development
The drug development paradigm for new central nervous system therapeutics is in need of a thorough reimagining, Tufts Center for the Study of Drug Development researchers assert in an analysis published in Scientific American.
Sounding The Alarm On The Future Of CNS Drug Development
The drug development paradigm for new central nervous system therapeutics is in need of a thorough reimagining, Tufts Center for the Study of Drug Development researchers assert in an analysis published in Scientific American.
At PSA, Meet The New Deal-Makers (Part 1)
Two of the biopharma industry's newest heads of business development talked with Elsevier Business Intelligence Editor-in-Chief Chris Morrison at the Pharmaceutical Strategic Alliances conference on Sept. 22 in New York.